Albireo Total Liabilities vs Current Assets Analysis

Summary

ALBODelisted Stock

USD 44.15 0.75 1.67%

Albireo Pharma financial indicator trend analysis is way more than just evaluating Albireo Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Albireo Pharma is a good investment. Please check the relationship between Albireo Pharma Total Liabilities and its Current Assets accounts. Please continue to Trending Equities.

Total Liabilities vs Current Assets

Total Liabilities vs Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Albireo Pharma Total Liabilities account and Current Assets. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Albireo Pharma's Total Liabilities and Current Assets is 0.98. Overlapping area represents the amount of variation of Total Liabilities that can explain the historical movement of Current Assets in the same time period over historical financial statements of Albireo Pharma, assuming nothing else is changed. The correlation between historical values of Albireo Pharma's Total Liabilities and Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liabilities of Albireo Pharma are associated (or correlated) with its Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Assets has no effect on the direction of Total Liabilities i.e., Albireo Pharma's Total Liabilities and Current Assets go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Liabilities

Deferred Income Tax is recorded on Albireo Pharma balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Albireo Pharma books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; [DeferredRev]; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.

Current Assets

Current assets of Albireo Pharma include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Albireo Pharma. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Most indicators from Albireo Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Albireo Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please continue to Trending Equities.Albireo Pharma Selling General and Administrative Expense is very stable at the moment as compared to the past year. Albireo Pharma reported last year Selling General and Administrative Expense of 80 Million. As of 20th of March 2023, Issuance Purchase of Equity Shares is likely to grow to about 3.3 M, while Net Cash Flow Business Acquisitions and Disposals is likely to drop about 99.9 M.

	2020	2021	2022	2023 (projected)
Revenues USD	8.31 M	40.58 M	46.67 M	50.35 M
Revenues	8.31 M	40.58 M	46.67 M	50.35 M

Revenues USD Revenues

Albireo Pharma fundamental ratios Correlations

	Inventories	Receivables	Accounts Payable	Total Assets	Current Assets	Assets Non Current	Cash and Equivalents	Total Debt	Debt Current	Debt Non Current	Shareholders Equity	Goodwill and Intangible Assets	Inventory	Total Liabilities	Current Liabilities	Liabilities Non Current	Trade and Non Trade Payables	Property Plant and Equipment Net	Trade and Non Trade Receivables	Tax Assets	Tax Liabilities
Inventories		-0.44	-0.55	-0.7	-0.69	-0.68	-0.68	-0.51	-0.69	-0.52	-0.66	-0.29	1.0	-0.72	-0.79	-0.67	-0.69	0.0	-0.56	0.18	0.34
Receivables	-0.44		0.96	0.91	0.91	0.85	0.91	0.74	0.8	0.82	0.9	0.6	-0.44	0.9	0.79	0.93	0.93	-0.18	0.95	-0.43	-0.47
Accounts Payable	-0.55	0.96		0.96	0.96	0.9	0.96	0.74	0.82	0.82	0.95	0.52	-0.55	0.95	0.87	0.96	0.94	-0.02	0.89	-0.28	-0.35
Total Assets	-0.7	0.91	0.96		1.0	0.93	1.0	0.74	0.86	0.82	0.99	0.49	-0.7	0.98	0.94	0.98	0.96	-0.03	0.87	-0.32	-0.41
Current Assets	-0.69	0.91	0.96	1.0		0.91	1.0	0.75	0.84	0.8	0.99	0.47	-0.69	0.98	0.93	0.99	0.95	-0.01	0.87	-0.3	-0.4
Assets Non Current	-0.68	0.85	0.9	0.93	0.91		0.91	0.61	0.97	0.95	0.93	0.63	-0.68	0.91	0.92	0.88	0.91	-0.19	0.79	-0.41	-0.49
Cash and Equivalents	-0.68	0.91	0.96	1.0	1.0	0.91		0.75	0.84	0.8	0.99	0.46	-0.68	0.98	0.92	0.99	0.95	-0.01	0.87	-0.3	-0.39
Total Debt	-0.51	0.74	0.74	0.74	0.75	0.61	0.75		0.56	0.52	0.74	0.31	-0.51	0.73	0.63	0.76	0.75	0.06	0.75	-0.22	-0.3
Debt Current	-0.69	0.8	0.82	0.86	0.84	0.97	0.84	0.56		0.98	0.87	0.67	-0.69	0.83	0.84	0.8	0.84	-0.29	0.75	-0.44	-0.54
Debt Non Current	-0.52	0.82	0.82	0.82	0.8	0.95	0.8	0.52	0.98		0.84	0.71	-0.52	0.77	0.77	0.75	0.8	-0.34	0.72	-0.47	-0.54
Shareholders Equity	-0.66	0.9	0.95	0.99	0.99	0.93	0.99	0.74	0.87	0.84		0.45	-0.66	0.96	0.9	0.96	0.92	-0.01	0.84	-0.3	-0.39
Goodwill and Intangible Assets	-0.29	0.6	0.52	0.49	0.47	0.63	0.46	0.31	0.67	0.71	0.45		-0.29	0.52	0.56	0.49	0.65	-0.76	0.63	-0.65	-0.67
Inventory	1.0	-0.44	-0.55	-0.7	-0.69	-0.68	-0.68	-0.51	-0.69	-0.52	-0.66	-0.29		-0.72	-0.79	-0.67	-0.69	0.0	-0.56	0.18	0.34
Total Liabilities	-0.72	0.9	0.95	0.98	0.98	0.91	0.98	0.73	0.83	0.77	0.96	0.52	-0.72		0.96	0.99	0.98	-0.06	0.9	-0.33	-0.43
Current Liabilities	-0.79	0.79	0.87	0.94	0.93	0.92	0.92	0.63	0.84	0.77	0.9	0.56	-0.79	0.96		0.92	0.94	-0.12	0.81	-0.36	-0.47
Liabilities Non Current	-0.67	0.93	0.96	0.98	0.99	0.88	0.99	0.76	0.8	0.75	0.96	0.49	-0.67	0.99	0.92		0.97	-0.03	0.92	-0.31	-0.4
Trade and Non Trade Payables	-0.69	0.93	0.94	0.96	0.95	0.91	0.95	0.75	0.84	0.8	0.92	0.65	-0.69	0.98	0.94	0.97		-0.2	0.94	-0.43	-0.52
Property Plant and Equipment Net	0.0	-0.18	-0.02	-0.03	-0.01	-0.19	-0.01	0.06	-0.29	-0.34	-0.01	-0.76	0.0	-0.06	-0.12	-0.03	-0.2		-0.31	0.82	0.78
Trade and Non Trade Receivables	-0.56	0.95	0.89	0.87	0.87	0.79	0.87	0.75	0.75	0.72	0.84	0.63	-0.56	0.9	0.81	0.92	0.94	-0.31		-0.51	-0.58
Tax Assets	0.18	-0.43	-0.28	-0.32	-0.3	-0.41	-0.3	-0.22	-0.44	-0.47	-0.3	-0.65	0.18	-0.33	-0.36	-0.31	-0.43	0.82	-0.51		0.98
Tax Liabilities	0.34	-0.47	-0.35	-0.41	-0.4	-0.49	-0.39	-0.3	-0.54	-0.54	-0.39	-0.67	0.34	-0.43	-0.47	-0.4	-0.52	0.78	-0.58	0.98

Click cells to compare fundamentals

Albireo Pharma Account Relationship Matchups

Albireo Pharma fundamental ratios Accounts

	2018	2019	2020	2021	2022	2023 (projected)
Accounts Payable	4.35 M	4.79 M	5.28 M	6.52 M	5.86 M	6.33 M
Accumulated Other Comprehensive Income	4.29 M	6.45 M	(8.61 M)	1.1 M	994.5 K	916.74 K
Total Assets	185.47 M	165.07 M	285.61 M	302.05 M	347.36 M	374.78 M
Current Assets	167.65 M	141.8 M	261.87 M	268.93 M	309.27 M	333.69 M
Assets Non Current	17.82 M	23.27 M	23.74 M	33.12 M	38.09 M	41.1 M
Cash and Equivalents	163.88 M	131.84 M	251.27 M	248.11 M	285.32 M	307.85 M
Cash and Equivalents USD	163.88 M	131.84 M	251.27 M	248.11 M	285.32 M	307.85 M
Shareholders Equity	122.64 M	93.16 M	181.23 M	175.61 M	201.95 M	217.89 M
Shareholders Equity USD	122.64 M	93.16 M	181.23 M	175.61 M	201.95 M	217.89 M
Total Liabilities	62.83 M	71.91 M	104.38 M	126.44 M	145.41 M	156.89 M
Current Liabilities	12.82 M	18.92 M	25.28 M	45.35 M	52.15 M	56.27 M
Liabilities Non Current	50 M	52.98 M	79.09 M	81.1 M	93.26 M	100.62 M
Trade and Non Trade Payables	4.35 M	4.79 M	5.28 M	6.52 M	7.49 M	8.08 M
Property Plant and Equipment Net	187 K	597 K	478 K	668 K	601.2 K	536.5 K
Accumulated Retained Earnings Deficit	(96.47 M)	(159.19 M)	(266.82 M)	(300.85 M)	(270.76 M)	(277.89 M)

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-	0.85	ABIO	ARCA Biopharma	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.74	ACER	Acer Therapeutics	Financial Report 15th of May 2023	Pair Corr
-	0.55	AADI	Aadi Bioscience	Financial Report 11th of May 2023	Pair Corr
-	0.53	ACGN	Aceragen	Symbol Change	Pair Corr

The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.

The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.

	Watchlist Optimization Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC